Immunodiagnostic Systems Hldgs PLC Launch of assay to detect SARS-CoV-2 antibodies (4352R)

TIDMIDH

RNS Number : 4352R

Immunodiagnostic Systems Hldgs PLC

30 June 2020

Immunodiagnostic Systems Holdings plc.

30 June 2020

Launch of automated assay to detect SARS-CoV-2 antibodies

Immunodiagnostic Systems Holdings plc (IDS), a specialty solution provider to the clinical laboratory diagnostic market, announces that following the announcement on 12 June, our fully automated SARS-CoV-2 IgG antibody test ("the Test") will be available for sale from today.

The test can now be purchased by customers in the UK, the EU, and a number of other countries which accept the CE mark as the basis of regulatory approval. We have commenced the process of working with various national reference centers and governmental bodies to ensure a roll-out according to national guidelines.

Jaap Stuut, CEO of IDS commented

"We are pleased to announce the release to the market of our automated SARS -CoV-2 antibody test, running on the IDS-iSYS analyser. IDS will now seek to commercialise this test via our direct sales force in Europe, and through our extensive distribution network elsewhere, and we look forward to joining the efforts to minimise the impact of the COVID-19 virus."

About the Test

The Test, which arises from the partnership between IDS and Technogenetics, is designed to run on the installed base of over 600 automated IDS-iSYS analysers. The Test:

-- Detects specific IgG antibodies indicating past exposure to the COVID-19 virus and immune response;

   --   Is a quantitative test which determines antibody concentration (titer); 
   --   Is highly accurate with a sensitivity of 100% and a specificity of 99.4%; 
   --   Provides Test results available within 25 minutes.

Unlike many COVID-19 serology assays currently available, this Test is a quantitative assay, thus it can determine the antibody concentration in patient serum. Although the clinical level of functional immunity conferred by SARS-CoV-2 IgG antibodies has not yet been determined, we believe quantitative tests may ultimately be valuable in determining immunity status based on the levels of antibody in the blood.

All steps of the Test are automated with no manual reagent preparation required, ensuring minimal hands-on time for lab staff and a high daily throughput.

For further information:

   Immunodiagnostic Systems Holdings plc               Tel: +44 (0) 191 519 6111

Jaap Stuut, Chief Executive Officer

Paul Martin, Group Finance Director

Peel Hunt LLP Tel: +44 (0) 20 7418 8900

James Steel

Oliver Jackson

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

PRLZZGZVVLNGGZM

(END) Dow Jones Newswires

June 30, 2020 02:00 ET (06:00 GMT)

Immunodiagnostic Systems (LSE:IDH)
Historical Stock Chart
From Jun 2024 to Jul 2024